MSN has failed to convince the Federal Circuit to invalidate three Cabometyx patents, preserving a January 2030 launch ...

The Bridge program may have enrolled 15% of eligible Part D beneficiaries after just two months, which raises questions about ...

Roughly half of the FDA applications with September user fee goal dates involve pediatric populations, including four novel ...

Nov. 12 deadline for limiting all THC to 0.3% concentration and 0.4mg per-container limit along with ban on synthetics ...

Targeting patients with the TP53 Y220C mutation, thought to be present in about 3.2% of ovarian cancer cases, PMV says ...

Memorandum of understanding between the two agencies allows them to share non-public information in order to improve ...

The company still plans to file an NDA for envudeucitinib for psoriasis and said a prespecified analysis in the Phase IIb ...

The UK medicines regulator has set its sights on making a global pharmacovigilance harmonization initiative more ...

September will see a busier medical meeting schedule with upcoming conferences including the ERS respiratory meeting, and ...

Aurobindo has confirmed that its Lannett subsidiary has launched its US generic rival to Advair. But almost seven years since ...

Team-NB heads consortium to develop open-source, single-entry-point digital assessment framework to replace “onerous” ...

In amendments to the Health Bill, government says it wants to give new powers the UK’s regulator that could allow it to ...